Literature DB >> 7108151

Serum thyroglobulin in patients undergoing subtotal thyroidectomy for toxic and nontoxic goiter.

U Feldt-Rasmussen, P H Petersen, J Date, C M Madsen.   

Abstract

Twenty-five patients with nontoxic nodular goiters and six with toxic goiter were studied prior to subtotal thyroidectomy, with closely spaced blood sampling up to three weeks after surgery, and approximately one year after surgery. Serum thyroglobulin (Tg) was measured by a previously described radioimmunological method. The mean serum Tg was elevated in patients with nontoxic nodular and toxic goiters compared to sex and age matched control groups with pronounced increases during surgery. The disappearance curves of Tg in both groups had two exponentials, an initial steep slope with a half-life of 4.0 +/- 1.8 (SD) h in nontoxic goiter and 4.5 +/- 3.2 h in toxic goiter. This was followed by a more shallow slope with a half-life of 3.6 +/- 1.1 days in nontoxic goiter and 3.4 +/- 0.8 h in toxic goiter, the breaking point between the slopes lying approximately at 48-72 h. There was no significant difference between the half-life of Tg in patients with toxic or nontoxic goiters, respectively. There was a weak correlation between the weight of the removed thyroid tissue and the maximally obtained Tg concentration at the time of surgery, but no correlation with the levels before operation. Serum Tg was significantly lower three weeks after operation and approximately one year after surgery. In conclusion, different forms of the Tg molecules seem to be removed at different rates, independent on the type of goiter.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7108151     DOI: 10.1007/BF03349472

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  17 in total

1.  Determination of serum-thyroglobulin by a haemagglutination-inhibition test.

Authors:  T HJORT
Journal:  Lancet       Date:  1961-06-10       Impact factor: 79.321

2.  Immunochemistry of the interaction of thyroglobulin (Tg) and its auto- and hetero antibodies.

Authors:  G B Salabé
Journal:  Acta Endocrinol Suppl (Copenh)       Date:  1975

3.  Effect of therapy on serum thyroglobulin levels in patients with Graves' disease.

Authors:  R P Uller; A J Van Herle
Journal:  J Clin Endocrinol Metab       Date:  1978-05       Impact factor: 5.958

4.  The role of sialic acid in determining the survival of glycoproteins in the circulation.

Authors:  A G Morell; G Gregoriadis; I H Scheinberg; J Hickman; G Ashwell
Journal:  J Biol Chem       Date:  1971-03-10       Impact factor: 5.157

5.  Serum thyroglobulin levels in healthy subjects and in patients with thyroid disease.

Authors:  G Torrigiani; D Doniach; I M Roitt
Journal:  J Clin Endocrinol Metab       Date:  1969-03       Impact factor: 5.958

6.  Clearance of normal and tumor-related thyroglobulin from the circulation of rats: role of the terminal sialic acid residues.

Authors:  K Ikekubo; R Pervos; A B Schneider
Journal:  Metabolism       Date:  1980-07       Impact factor: 8.694

7.  Thyroglobulin of varying molecular sizes with different disappearance rates in plasma following subtotal thyroidectomy.

Authors:  U Feldt-Rasmussen; P H Petersen; H Nielsen; J Date; C M Madsen
Journal:  Clin Endocrinol (Oxf)       Date:  1978-09       Impact factor: 3.478

8.  Serum thyroglobulin in patients with toxic and non-toxic goitres compared to sex- and age-matched control subjects.

Authors:  U Feldt-Rasmussen; K Bech; J Date
Journal:  Acta Endocrinol (Copenh)       Date:  1979-06

9.  Sex and age correlated reference values of serum thyroglobulin measured by a modified radioimmunoassay.

Authors:  U Feldt-Rasmussen; P Hyltoft Petersen; J Date
Journal:  Acta Endocrinol (Copenh)       Date:  1979-03

10.  Increased sensitivity of the thyroid in iodine-depleted rats to the goitrogenic effects of thyrotropin.

Authors:  G A Bray
Journal:  J Clin Invest       Date:  1968-07       Impact factor: 14.808

View more
  4 in total

Review 1.  Controversies in the Management of Low-Risk Differentiated Thyroid Cancer.

Authors:  Megan R Haymart; Nazanene H Esfandiari; Michael T Stang; Julia Ann Sosa
Journal:  Endocr Rev       Date:  2017-08-01       Impact factor: 19.871

2.  Thyroid function in patients with Pendred's syndrome.

Authors:  J Friis; T Johnsen; U Feldt-Rasmussen; K Bech; T Friis
Journal:  J Endocrinol Invest       Date:  1988-02       Impact factor: 4.256

3.  Serum thyroglobulin concentration in nontoxic goiter and response to surgery with special reference to risk of goiter relapse.

Authors:  U Feldt-Rasmussen; M Blichert-Toft; J Date; V Haas
Journal:  World J Surg       Date:  1986-08       Impact factor: 3.352

Review 4.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky
Journal:  Thyroid       Date:  2016-01       Impact factor: 6.568

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.